Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SRSF6 | Q13247 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016238 | 0.93 | ADRB2 (0.39) | ADRB2ADRB1DRD3SLC6A2ADRA1D | |
| SCHEMBL17978658 | 0.91 | ADRB2 (0.42) | ADRB2ADRB1DRD3SLC6A2ADRA1D | |
| SCHEMBL18557604 | 0.87 | ADRB2 (0.40) | ADRB2ADRB1DRD3SLC6A2ADRA1D | |
| SCHEMBL28424321 | 0.85 | ADRB2 (0.41) | ADRB2ADRB1DRD3SLC6A2ADRA1D | |
| SCHEMBL17978747 | 0.85 | ADRB2 (0.41) | ADRB2ADRB1DRD3SLC6A2ADRA1D | |
| SCHEMBL28423956 | 0.85 | ADRB2 (0.41) | ADRB2ADRB1DRD3SLC6A2ADRA1D | |
| SCHEMBL19770230 | 0.82 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL19770232 | 0.82 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL14643021 | 0.82 | ADRB2 (0.45) | ADRB2ADRB1 | |
| SCHEMBL17979058 | 0.82 | ADRB2 (0.40) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | disclosed |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-26 | — | — | US | disclosed |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-04 | — | — | US | disclosed |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-04 | — | — | US | disclosed |
| US-9579314-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-28 | — | — | US | disclosed |
| US-9579314-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-28 | — | — | US | disclosed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885DRD3 1138/4885 |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885DRD3 1138/4885 |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885DRD3 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.